enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Editas Medicine Announces Third Quarter 2024 Results and ...

    lite.aol.com/tech/story/0022/20241104/9266630.htm

    On October 3, 2024, Editas Medicine announced the sale of certain future license fees and other payments owed to the Company under its Cas9 license agreement with Vertex Pharmaceuticals to a wholly owned subsidiary of DRI Healthcare Trust (DRI) for an upfront cash payment of $57 million.

  3. Editas Medicine Announces $50+ Million Monetization Financing ...

    lite.aol.com/tech/story/0022/20241003/9251178.htm

    CAMBRIDGE, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced the sale of certain future license fees and other payments owed to Editas Medicine under its Cas9 license agreement with Vertex Pharmaceuticals to a wholly-owned subsidiary of DRI Healthcare Trust (DRI) for an upfront cash payment of $57 million.

  4. Editas Medicine - Wikipedia

    en.wikipedia.org/wiki/Editas_Medicine

    Editas Medicine was originally founded with the name "Gengine, Inc." in September 2013 by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley, [7] and George Church, David Liu, and J. Keith Joung of Harvard University, with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures; the name was changed to the current "Editas Medicine" two ...

  5. Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal - AOL

    www.aol.com/news/editas-edit-beats-q3-earnings...

    Editas' (EDIT) portfolio currently lacks an approved product. The focus of third-quarter earnings call was on its pipeline development. Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal

  6. Vertex Pharmaceuticals - Wikipedia

    en.wikipedia.org/wiki/Vertex_Pharmaceuticals

    Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry .

  7. Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101 - AOL

    www.aol.com/news/editas-edit-focuses-developing...

    Editas (EDIT) progresses well on developing its lead candidate EDIT-101 to treat LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a concern.

  8. Better Buy: Editas Medicine vs. CRISPR Therapeutics - AOL

    www.aol.com/news/better-buy-editas-medicine-vs...

    For premium support please call: 800-290-4726 more ways to reach us

  9. File:Editas Medicine logo.svg - Wikipedia

    en.wikipedia.org/wiki/File:Editas_Medicine_logo.svg

    This file contains additional information, probably added from the digital camera or scanner used to create or digitize it. If the file has been modified from its original state, some details may not fully reflect the modified file.